Yield10 Bioscience, Inc.

YTEN

US98585K8541

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:06:53 14/06/2024 pm IST			5-day change	1st Jan Change
1.42 ^USD	-4.91%		-15.85%	-75.28%

20/05	Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index	CI
15/05	Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000	MT

Metabolix, Inc. will Change its Name to Yield10 Bioscience, Inc

January 09, 2017 at 10:30 am IST

Effective January 09, 2017, Metabolix, Inc. will change its name to Yield10 Bioscience, Inc.

Latest news about Yield10 Bioscience, Inc.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index	20/05	CI
Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000	16/05	MT
Yield10 Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Top Midday Decliners	15/05	MT
Yield10 Bioscience to Delist From Nasdaq; Shares Drop	15/05	MT
Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index	15/05	CI
Transcript : Yield10 Bioscience, Inc., Q4 2023 Earnings Call, Apr 01, 2024	02/04
Yield10 Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/04	CI
Yield10 Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada	26/03	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ
Top Midday Gainers	22/03	MT
Yield10 Bioscience, Inc. Grants Global License to VISION Bioenergy Oilseeds, LLC for Herbicide Tolerant Camelina Cultivated for Production of Biofuel Feedstock	14/02	CI
North American Morning Briefing : Stock Futures -2-	09/02	DJ
Lake Street Downgrades Yield10 Bioscience to Hold From Buy, Cuts Price Target to $0.50 From $3	08/02	MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	08/02	MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	08/02	MT
Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program	08/02	CI
Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil	08/01	CI
Transcript : Yield10 Bioscience, Inc., Q3 2023 Earnings Call, Nov 14, 2023	15/11
Yield10 Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Yield10 Bioscience, Inc. Contemplates Bankruptcy.	14/11	CI
Yield10 Bioscience, Inc. and Biomar Group Aim to Grow Fish Oil on Land	31/23/31	CI
Yield10 Bioscience, Inc. Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Production Technology from Rothamsted Research	20/23/20	CI
Sector Update: Health Care Stocks Softer Late Afternoon	19/23/19	MT

Chart Yield10 Bioscience, Inc.

Duration

Period

More charts

Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Yield10 Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.42 USD

Average target price

12 USD

Spread / Average Target

+745.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
YIELD10 BIOSCIENCE, INC.	-75.28%	912K
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+34.52%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research

Yield10 Bioscience, Inc.

Equities

YTEN

US98585K8541

Biotechnology & Medical Research

Metabolix, Inc. will Change its Name to Yield10 Bioscience, Inc

Latest news about Yield10 Bioscience, Inc.

Chart Yield10 Bioscience, Inc.

Company Profile

Income Statement Evolution

Ratings for Yield10 Bioscience, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research